At the beginning of the new year, good news came from China's hepatitis B innovative drug research and development field, Zhongyi Haider Artificial Intelligence Drug Research and Development Company Limited (hereinafter referred to as "Zhongyi Haider") recently announced that four of its hepatitis B innovative drugs have completed drug biology verification, and will work together with Prof. Wei Lai, Vice President of Beijing Tsinghua Changgeng Hospital, to launch real-world studies around the clinical research of the four drugs. The team will work with Prof. Wei Lai, Vice President of Tsinghua Changgeng Hospital in Beijing, and Tigermed to launch real-world studies around the clinical research of these four drugs.
It is worth noting that the four Hepatitis B Program Innovative Drugs took only 90 days from the start of screening to entering clinical studies, which is about 30 times faster compared to the speed of traditional pharmaceutical companies at this stage of development.
At a time when the "AI+New Drug R&D" model is gradually being emphasized by the industry, CIICH's practice has brought new inspiration to the industry's innovative drug R&D, and may redefine "drug discovery".
China-Israel Hyder is committed to building the world's first artificial intelligence new drug R&D incubation platform, which is initiated by Roger Kornberg, American scientist, professor of structural biology at Stanford University, and 2006 Nobel Prize Laureate in Chemistry; Wang Shi, Honorary Chairman of the Board of Directors of Vanke; and Chen Mingji, founder of Oriental Gaoxin, a well-known investment institution in the field of health, at the end of 2019. The first phase of the goal is dedicated to the development of innovative drugs that functionally cure hepatitis B.
Chen Mingjian, Founder of China-Israel-Hyder
Chen Mingjian, Founder of China-Israel-Hyder, said China-Israel-Hyder has three revolutionary efforts: first, combining the strongest brains of Israeli scientists and the diligence of Chinese scientists to make the most rooted efforts through the global grass-roots innovation model; second, the revolution of drug efficacy validation, which is a revolution in the way that, compared to the traditional clinical study, whether some of the steps can be carried out at the same time, and whether the mechanism can be changed; third, the revolution of pharmaceutical R&D. can be changed; third is the artificial intelligence revolution in the field of pharmaceutical research and development, relying on artificial intelligence to quickly find effective drugs.
From "fetishism" to "from 0 to 1"
The band purchasing has led to the fall of the era of generic drugs and the arrival of the era of innovative drugs, coupled with the weak foundation of the domestic research and development of new drugs, resulting in "fetishism". The result is the prevalence of "fetishism", the direct introduction of innovative drugs from abroad, the authorization of the transaction mode has become the mainstream mode of domestic pharmaceutical enterprises.
However, China-Israel-Hyder is committed to the most basic and cutting-edge "0 to 1" new drug research and development, hoping to gather the strongest brains of Jewish scientists, "transplant" the Israeli "0 to 1" innovation gene, and "transplant" the Israeli "0 to 1" innovation gene, and "transplant" the Israeli "0 to 1" innovation gene, and "transplant" the Israeli "0 to 1" innovation gene. We hope to gather the strongest brains of Jewish scientists, "transplant" Israel's "0 to 1" innovation gene, and combine it with domestic scientists' diligence and rich on-the-ground practice, and start from fundamental R&D. All the research results are independent intellectual property rights. All research results are independent intellectual property rights.
It is understood that China-Israel Hyde has set up a laboratory in Israel at the early stage of its establishment, and Avraham Schroeder, a professor at Haifa Polytechnic, is the CEO.
In Wang Shi's view, the reason why the laboratory (incubator) was set up in Israel at the beginning rather than in China according to the general custom is mainly due to the innovation atmosphere and source of power. considerations. "As of now, there are 138 Sino-Israeli entrepreneurial parks created in China, and the number is still increasing, but frankly speaking, this kind of hope that Israeli experts will come over, and China will pay for all the money, material, and equipment is not the right logic. Innovation is the essence of Jewish survival, but it is very difficult to come to China and innovate apart from their religion, community, and culture."
Wang Shi, Director of China-Israel-Hyder and Honorary Chairman of the Board of Directors of Vanke Group
Wang Shi believes that the most important thing to really establish an incubator is not to acquire technology, but to exchange concepts, ideas, "but it's not that what happens when you go there, but the most important thing is to integrate and establish a relationship of trust, and it should be said that China-Israel-Hyder builds a platform for exchange of Chinese and Israeli scientists in This aspect took the lead to take a step forward."
Chen Mingjian introduced, the current business layout of China-Israel Hyder includes three aspects: First, old drugs for new use, through the screening of thousands of existing drugs, to further excavate new drugs with special efficacy for hepatitis B, the preliminary experiments have screened out four drugs, that is, the aforementioned four hepatitis B project to enter the real-world study of the innovative drugs; Second, the real discovery of new molecules, the current has been screened out 86 compounds from 2.1 billion small molecules, which is the first step in the discovery of new molecules, the first step in the discovery of new molecules. molecules inside the screening of 86 compounds, and has entered the experimental stage; third, is actively developing several Chinese medicines, the subsequent will be directly commercialized.
The reason why CIIC Hyder has made functional treatment of hepatitis B as its first target is that China is a major hepatitis B country, and about 1/3 of the world's hepatitis B carriers are in China. A Lancet article titled "Hepatitis B in China" writes that 120 million hepatitis B carriers live in China. Hepatitis B causes about 30% to 45% of cirrhosis and liver cancer patients worldwide, and in China the rates are as high as 60% and 80%. However, Hepatitis B is a rare disease in foreign countries and is not the focus of pharmaceutical research and development, so there is no functional cure for Hepatitis B at this time.
AI Enabling, efficiency and cost reduction
Many industry insiders generally believe that China's biomedical industry has been in the upward trend, and in the future it is likely to become the world's largest market, but the biggest problem is the cost. Contrary to Moore's Law (a theory that the cost of the same technology gradually decreases over time as technology advances), the cost of pharmaceutical research and development is on the rise, basically doubling the cost of making a drug every ten years, and it now costs an average of $2.6 billion to develop a drug. The second big problem I is that it takes a long time, 4 to 7 years before clinical trials and 5 to 8 years in the clinic.
It is in this context that AI technology is beginning to attract attention in the industry. Dr. Yingying Li, Chief Scientist of China-Israel Haider, introduced that China-Israel Haider has collected a full range of histological data for the hepatitis B population and analyzed and organized the research by combining it with the real-world clinical data, and empowered it with AI technology in the whole process of screening from pathology to drug screening and drug incubation. Firstly, based on Hi-C three-dimensional genetic testing technology, we utilize artificial intelligence to collect and analyze the pathological data of the disease with high quality, forming a 100,000-person quantitative hepatitis B database, revealing the susceptibility gene mechanism of viral hepatitis through the genomic data of the large population, and then establishing a biological process model based on the measurement data and molecular data of the compounds to analyze and predict the functions of different kinds of compounds and compound-related properties in the developed drugs. Compound-related properties are analyzed and predicted, and finally the exploration process is shortened to a few months through AI screening, which ensures precision in detection and screening, and improves efficiency and saves costs in multiple aspects of drug incubation, realizing the precise and efficient path of drug development.
"Traditional R&D is done from a target, but if the target is wrongly selected at the beginning, all is useless in the future, AI algorithms can skip the uncertainty of a single target, and directly establish a connection between the drug and its efficacy, and the key point is not only a target, but also look at bioinformatics, genes, and patient test data, so that in fact, it is adding to its uncertainty. is to add a lot of certainty to its uncertainty, the accuracy will be a little higher, not only save time and lower cost." Li Yingying said.
It is worth noting that the deepening of the pharmaceutical band purchasing, and many biomedical innovation drug companies require the return of a relatively large conflict, such as this year's PD-1 health insurance prices will fall to less than $ 10,000, many monoclonal antibody drugs may be reduced to 500 to 1,000 yuan range.
With expectations shattered, is innovation still a thing?
Chen Mingji believes that the prosperity of the pharmaceutical industry in the next ten years comes from commercial insurance, especially the prosperity of innovative drugs certainly comes from commercial insurance, so for innovative drugs, to get back the dividends of innovation, you may have to keep your eyes on the commercial insurance.
Wang Shi in recent years is committed to promoting exchanges between China and Israel at all levels, China-Israel Hyde project is a major achievement, "China-Israel exchanges itself is what I am interested in, and the use of AI technology to develop new medicines is also very much worth looking forward to, and I think that this kind of exploration is very worthwhile." Wang Shi said.
China-Israel-Hyder's three major revolutionary work in the field of pharmaceutical research and development is currently attracting attention from all sectors of society. It is reported that in the "Foresight 2060: Sustainable Development in China" summit forum organized by the Economic Observer on January 28, China-Hyder was awarded the "Practicing Sustainable Development '0 to 1' Innovative Enterprises" honor.
Zhang Li / article